NASDAQ
8.78USD
+0.17 (+1.92%)
We have scored 89 news catalysts on ADMA Biologics, Inc. (ADMA) over the past 12 months. The biggest single-day move next to one of them came Jun 15, 2026, when ADMA closed +3.5%: “ADMA Shareholder News: ADMA Biologics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law about the Ongoing Securities Class Action”. Coverage across the window leans negative (average ticker sentiment −0.72). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
0.77
52W range
7.21-20.458
Day range
8.54–8.79
Open
8.59
Prev close
8.61
Volume
339.8K
Avg volume
4.5M
Dividend
0.00
IPO
2013-10-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ADMA Biologics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ADMA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
